Literature DB >> 25174906

Small molecule inhibitors in veterinary oncology practice.

Cheryl A London1.   

Abstract

Recent advances in molecular biology have permitted the identification and characterization of specific abnormalities regarding cell signaling and function in cancer cells. Proteins that are found to be dysregulated in cancer cells can serve as relevant targets for therapeutic intervention. Although there are several approaches to block proteins that contribute to cellular dysfunction, the one most commonly used involves a class of therapeutics called small molecule inhibitors. Such inhibitors work by disrupting critical pathways/processes in cancer cells, thereby preventing their ability to grow and survive.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dog; Inhibitor; Kinase; Protein

Mesh:

Substances:

Year:  2014        PMID: 25174906     DOI: 10.1016/j.cvsm.2014.06.001

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  3 in total

1.  Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

Authors:  R Mani; R Yan; X Mo; C-S Chen; M A Phelps; R Klisovic; J C Byrd; W C Kisseberth; C A London; N Muthusamy
Journal:  Vet Comp Oncol       Date:  2016-05-02       Impact factor: 2.613

2.  Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines.

Authors:  Fernando Ferreira; Raquel Chaves; Daniela Ferreira; Maria Soares; Jorge Correia; Filomena Adega
Journal:  Aging (Albany NY)       Date:  2019-07-12       Impact factor: 5.682

3.  Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells.

Authors:  Yusuke Murase; Kenji Hosoya; Takachika Sato; Sangho Kim; Masahiro Okumura
Journal:  Oncol Rep       Date:  2022-01-28       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.